Treatment Clinical Trials for Malignant Mesothelioma

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest

Clinical trials are research studies that involve people. The clinical trials on this list are for malignant mesothelioma treatment. All trials on the list are supported by NCI.

NCI’s basic information about clinical trials explains the types and phases of trials and how they are carried out. Clinical trials look at new ways to prevent, detect, or treat disease. You may want to think about taking part in a clinical trial. Talk to your doctor for help in deciding if one is right for you.

Trials 1-25 of 38
1 2 Next >

  • Atezolizumab, Pemetrexed Disodium, Cisplatin, and Surgery with or without Radiation Therapy in Treating Patients with Stage I-III Pleural Malignant Mesothelioma

    This phase I pilot trial studies how well atezolizumab, pemetrexed disodium, cisplatin, and surgery with or without radiation therapy in treating patients with stage I-III pleural malignant mesothelioma. Monoclonal antibodies, such as atezolizumab, may interfere with the ability of tumor cells to grow and spread. Pemetrexed disodium may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as cisplatin, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving atezolizumab, pemetrexed disodium, and cisplatin before surgery may make the tumor smaller and reduce the amount of normal tissue that needs to be removed. Giving atezolizumab after surgery may kill any remaining tumor cells.
    Location: 139 locations

  • Phase II MEDI4736 in Combination With Chemotherapy for First-Line Treatment of Unresectable Mesothelioma

    Patients with pleural mesothelioma that can not be surgically removed will receive durvalumab, in combination with standard chemotherapy of pemetrexed and cisplatin as first-line treatment. Durvalumab is a type of drug called a monoclonal antibody (a type of protein). Laboratory tests show that it works by allowing the immune system to detect your cancer and reactivates the immune response. This may help to slow down the growth of cancer or may cause cancer cells to die. The purpose of this study is to see whether adding durvalumab to standard chemotherapy will improve overall survival (OS).
    Location: 11 locations

  • Methoxyamine, Cisplatin, and Pemetrexed Disodium in Treating Patients with Advanced Solid Tumors or Mesothelioma That Cannot Be Removed by Surgery or Mesothelioma That Is Refractory to Pemetrexed Disodium and Cisplatin or Carboplatin

    This phase I / II trial studies the side effects and the best dose of methoxyamine when given together with cisplatin and pemetrexed disodium and to see how well it works in treating patients with solid tumors or mesothelioma that have spread to other places in the body and usually cannot be cured or controlled with standard treatment (advanced), or mesothelioma that does not respond to pemetrexed disodium and cisplatin or carboplatin (refractory). Methoxyamine may shrink the tumor and may also help cisplatin and pemetrexed disodium work better by making tumor cells more sensitive to the drugs. Drugs used in chemotherapy, such as cisplatin and pemetrexed disodium, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving methoxyamine together with cisplatin and pemetrexed disodium may be a better treatment for solid tumors or mesothelioma.
    Location: 12 locations

  • Ph 2 / 3 Study in Subjects With MPM w / Low ASS 1 Expression to Assess ADI-PEG 20 With Pemetrexed and Cisplatin

    This is a study of ADI-PEG 20 (pegylated arginine deiminase), an arginine degrading enzyme versus placebo in patients with malignant pleural mesothelioma with low argininosuccinate synthetase 1 expression. Malignant pleural mesothelioma have been found to require arginine, an amino acid. Thus the hypothesis is that by restricting arginine with ADI-PEG 20, the malignant pleural mesothelioma cells will starve and die.
    Location: 8 locations

  • Safety Study of Enoblituzumab (MGA271) in Combination With Pembrolizumab in Refractory Cancer

    The purpose of this study is to evaluate the safety of enoblituzumab (MGA271) in combination with Keytruda (pembrolizumab) when given to patients with B7-H3-expressing melanoma, squamous cell carcinoma of the head and neck (SCCHN), non small cell lung cancer (NSCLC), Urothelial Cancer and other B7-H3 expressing cancers. The study will also evaluate what is the highest dose of enoblituzumab that can be given safely when given with pembrolizumab. Assessments will also be done to see how the drug acts in the body (pharmacokinetics (PK), pharmacodynamics) and to evaluate potential anti-tumor activity of MGA271 in combination with pembrolizumab.
    Location: 7 locations

  • Surgery, Chemotherapy, and Intensity Modulated Radiation Therapy in Treating Patients with Stage I-III Pleural Mesothelioma

    This phase II trial studies the side effects of surgery, chemotherapy, and intensity modulated radiation therapy in treating patients with stage I-III pleural mesothelioma. Drugs used in chemotherapy, such as pemetrexed disodium, cisplatin, and carboplatin, work in different ways to stop the growth of cancer, either by killing the cancer cells, by stopping them from dividing, or by stopping them from spreading. Intensity modulated radiation therapy uses high-energy x-rays to kill tumor cells and shrink tumors. Giving chemotherapy before radiation therapy may help kill more tumor cells after surgery.
    Location: 7 locations

  • Avelumab and Stereotactic Body Radiation Therapy in Treating Patients with Malignant Mesothelioma

    This phase I / II trial studies how well avelumab and stereotactic body radiation therapy work in treating patients with malignant mesothelioma. Monoclonal antibodies, such as avelumab, may interfere with the ability of tumor cells to grow and spread. Stereotactic body radiation therapy is a specialized radiation therapy that sends x-rays directly to the tumor using smaller doses over several days and may cause less damage to normal tissue. Giving avelumab and stereotactic body radiation therapy may work better in treating patients with malignant mesothelioma.
    Location: 6 locations

  • Pevonedistat with or without Pemetrexed Disodium and Cisplatin in Treating Patients with Malignant Mesothelioma

    This phase I / II trial studies the side effects and best dose of pevonedistat with or without pemetrexed disodium and cisplatin, and to see how well they work in treating patients with malignant mesothelioma. Pevonedistat may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as pemetrexed disodium and cisplatin, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving pevonedistat, pemetrexed disodium, and cisplatin may work better in treating patients with malignant mesothelioma.
    Location: 6 locations

  • A Dose-Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of IPI-549

    This dose-escalation study will evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of IPI-549 monotherapy and IPI-549 in combination with nivolumab in subjects with advanced solid tumors.
    Location: 8 locations

  • Safety and Efficacy of LAG525 Single Agent and in Combination With PDR001 in Patients With Advanced Malignancies.

    This study is to characterize the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD) and anti-tumor activity of LAG525 as a single agent and in combination with PDR001 to adult patients with solid tumors. The study consists of a dose escalation phase (I) to determine the maximum tolerated dose (MTD) or recommended Phase 2 dose (RP2D) for LAG525 as a single agent and in combination with PDR001, and a dose expansion phase (II) which will characterize treatment of LAG525 as a single agent and in combination with PDR001 at the MTD or RP2D.
    Location: 6 locations

  • Safety Study of MGD009 in B7-H3-expressing Tumors

    The purpose of this study is to evaluate the safety of MGD009 when given to patients with B7-H3-expressing tumors. The study will also evaluate what is the highest dose of MGD009 that can be given safely. Assessments will be done to see how the drug acts in the body (pharmacokinetics (PK), pharmacodynamics (PD) and to evaluate potential anti-tumor activity of MGD009.
    Location: 7 locations

  • Study of Nivolumab Combined With Ipilimumab Versus Pemetrexed and Cisplatin or Carboplatin as First Line Therapy in Unresectable Pleural Mesothelioma Patients

    The purpose of this study is to test the effectiveness and tolerability of the combination of Nivolumab and Ipilimumab compared to Pemetrexed and Cisplatin or Carboplatin in patients with unresectable pleural mesothelioma.
    Location: 3 locations

  • Dose Escalation and Expansion Study of GSK3359609 in Subjects With Selected Advanced Solid Tumors (INDUCE-1)

    GSK3359609 is an anti-Inducible T cell Co-Stimulator (ICOS) receptor agonist antibody intended for the treatment of cancers of different histology. This is a first-time-in-human (FTIH), open-label, multicenter study designed to investigate the safety, pharmacology, and preliminary antitumor activity in subjects with advanced or recurrent solid tumors with the aim to establish recommended dose(s) of GSK3359609 for further exploration as monotherapy and in combination with pembrolizumab or other immune therapies or anticancer therapies. The study is comprised of two primary parts, each composed of two phases: Part 1: GSK3359609 monotherapy with Part 1A as dose escalation phase and Part 1B as cohort expansion phase; Part 2: GSK3359609 combination therapy with Part 2A pembrolizumab combination dose escalation phase / safety run-in and Part 2B cohort expansion phase. GSK3359609 combinations with chemotherapy will only consist of safety run-in cohorts. Each part and phase of the study includes a screening period, a treatment period, and a follow-up period. The primary objective of the study is to determine the safety, tolerability, maximum tolerated dose or the maximum administered dose of GSK3359609 alone or in combination.
    Location: 3 locations

  • Tremelimumab and Durvalumab in Treating Patients with Malignant Pleural Mesothelioma That Cannot Be Removed by Surgery

    This phase II trial studies how well tremelimumab and durvalumab work in treating patients with malignant pleural mesothelioma that cannot be removed by surgery. Monoclonal antibodies such as tremelimumab and durvalumab, may interfere with the ability of tumor cells to grown and spread. Giving tremelimumab with durvalumab may be a better way to treat malignant pleural mesothelioma.
    Location: 2 locations

  • A Phase 1 / 2 Study to Investigate the Safety, Biologic and Anti-tumor Activity of ONCOS-102 in Combination With Durvalumab in Subjects With Advanced Peritoneal Malignancies

    This is a two-part Phase 1 / 2 dose escalation and dose expansion study of the GMCSFencoding adenovirus, ONCOS-102, in combination with anti-programmed death ligand-1 (PDL1) antibody, durvalumab, in adult subjects with peritoneal disease who have failed prior standard chemotherapy and have histologically confirmed platinum-resistant or refractory epithelial ovarian cancer or colorectal cancer.
    Location: 2 locations

  • Chemotherapy With or Without Porfimer Sodium-Based Photodynamic Therapy During Surgery in Treating Patients With Malignant Pleural Mesothelioma

    This randomized phase II trial studies how well chemotherapy with or without porfimer sodium-based photodynamic therapy during surgery works in treating patients with malignant pleural mesothelioma. Drugs used in chemotherapy, such as pemetrexed disodium, work in different ways to stop the growth of cancer, either by killing the cancer cells, by stopping them from dividing, or by stopping them from spreading. Photodynamic therapy uses a drug, such as porfimer sodium, that becomes active when it is exposed to a certain kind of light. When the drug is active, tumor cells are killed. It is not yet known whether chemotherapy is more effective with or without porfimer sodium-based photodynamic therapy during surgery in treating patients with malignant pleural mesothelioma.
    Location: 2 locations

  • Surgery With or Without Intraoperative Heated Cisplatin and Sodium Thiosulfate Followed by Pemetrexed Disodium and Cisplatin in Treating Patients With Malignant Pleural Mesothelioma

    RATIONALE: Drugs used in chemotherapy, such as cisplatin, work in different ways to stop the growth of cancer, either by killing the cancer cells or by stopping them from dividing. Heating a chemotherapy solution and infusing it directly into the abdomen may kill more tumor cells. Chemoprotective drugs, such as sodium thiosulfate, may protect normal cells from the side effects of chemotherapy. Pemetrexed disodium may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Chemotherapy, given before and after surgery, followed by pemetrexed disodium may be effective treatment for malignant pleural mesothelioma. PURPOSE: This randomized phase II trial is studying how well surgery with or without intraoperative heated cisplatin and sodium thiosulfate followed by pemetrexed disodium and cisplatin works in treating patients with malignant pleural mesothelioma.
    Location: 2 locations

  • LMB-100 and SEL-110 in Treating Participants with Malignant Pleural or Peritoneal Mesothelioma

    This phase I trial studies the side effects and best dose of LMB-100 when given together with SEL-110 in treating participants with malignant pleural or peritoneal mesothelioma. Monoclonal antibodies, such as LMB-100 and SEL-110, may interfere with the ability of tumor cells to grow and spread. Giving LMB-100 and SEL-110 may work better in treating participants with malignant pleural or peritoneal mesothelioma.
    Location: National Institutes of Health Clinical Center, Bethesda, Maryland

  • Pembrolizumab with or without Anetumab Ravtansine in Treating Patients with Mesothelin-Positive Pleural Mesothelioma

    This randomized phase I / II trial studies the side effects and how well pembrolizumab with or without anetumab ravtansine work in treating patients with mesothelin-positive pleural mesothelioma. Monoclonal antibodies, such as anetumab ravtansine and pembrolizumab, may interfere with the ability of tumor cells to grow and spread.
    Location: Mayo Clinic, Rochester, Minnesota

  • Brentuximab Vedotin in Treating Patients with CD30+ Malignant Mesothelioma That Cannot Be Removed by Surgery

    This phase II trial studies how well brentuximab vedotin works in treating patients with CD30+ malignant mesothelioma that cannot be removed by surgery. Monoclonal antibodies, such as brentuximab vedotin, may interfere with the ability of tumor cells to grow and spread.
    Location: M D Anderson Cancer Center, Houston, Texas

  • Pembrolizumab after Radiation Therapy in Treating Patients with Pleural Malignant Mesothelioma

    This phase I trial studies the side effects and best way to give pembrolizumab after radiation therapy in treating patients with pleural malignant mesothelioma. Radiation therapy uses high energy radiation to kill tumor cells and shrink tumors. Monoclonal antibodies, such as pembrolizumab, may interfere with the ability of tumor cells to grow and spread. Giving pembrolizumab after radiation therapy may kill more tumor cells.
    Location: M D Anderson Cancer Center, Houston, Texas

  • Plicamycin in Treating Patients with Primary Thoracic Malignancies or Carcinomas, Sarcomas, or Germ Cell Tumors with Pleuropulmonary Metastases

    This phase I / II trial studies the best dose and side effects of plicamycin and how well it works in treating patients with primary thoracic malignancies or carcinomas, sarcomas, or germ cell tumors that have spread to organs in the chest. Plicamycin may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
    Location: National Institutes of Health Clinical Center, Bethesda, Maryland

  • Heated Pemetrexed Disodium and Cisplatin during Surgery in Treating Participants with Pleural Malignant Mesothelioma

    This phase I trial studies the side effects and best dose of heated pemetrexed disodium when given together with heated cisplatin during surgeries such as extrapleural pneumonectomy or pleural decortication in treating participants with pleural malignant mesothelioma. Pemetrexed disodium may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as cisplatin, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Heating pemetrexed disodium and cisplatin and infusing them directly into the chest during the surgery may kill more tumor cells.
    Location: Baylor College of Medicine / Dan L Duncan Comprehensive Cancer Center, Houston, Texas

  • Thorough ECG (Electrocardiogram) and Drug Interaction Study With Anetumab Ravtansine and Itraconazole

    Characterize the safety, tolerability, ECG effects, pharmacokinetics and immunogenicity of anetumab ravtansine given as single agent and after inhibition of CYP3A4 and P-gp by concomitant administration of itraconazole in subjects with mesothelin-expressing advanced solid cancers
    Location: UCLA / Jonsson Comprehensive Cancer Center, Los Angeles, California

  • LMB-100 with or without Nab-Paclitaxel in Treating Patients with Mesothelin Positive Solid Tumors or Recurrent, Metastatic, and / or Locally Advanced Pancreatic Cancer

    This phase I / II trial studies the side effects and best dose of anti-mesothelin-pseudomonas exotoxin 24 cytolytic fusion protein LMB-100 (LMB-100) with or without nab-paclitaxel in treating patients with mesothelin positive solid tumors or pancreatic cancer that has come back and has spread to other places in the body. Immunotoxins, such as LMB-100, are antibodies linked to a toxic substance and may help find tumor cells that express the mesothelin protein and kill them without harming normal cells. Drugs used in chemotherapy, such as nab-paclitaxel, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. It is not yet known whether giving LMB-100 therapy with or without nab-paclitaxel may work in treating patients with mesothelin positive solid tumors or pancreatic cancer.
    Location: National Institutes of Health Clinical Center, Bethesda, Maryland


1 2 Next >